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Abstract 
Systemic lupus erythematosus (SLE) is a chronic disease with a broad spectrum of 
clinical manifestations and infections are a leading cause of morbidity and premature 
mortality in patients with SLE. Findings from previous studies may be limited because of 
small sample sizes and using prevalent cohorts. To evaluate the risk of severe infection 
and infection-related mortality among patients with newly diagnosed SLE. We conducted 
an age- and gender- matched cohort study of all patients with incident SLE using 
administrative health data from British Columbia, Canada. Primary outcome was the first 
severe infection after SLE onset. Secondary outcomes were total number of severe 
infections and infection-related mortality. Multivariable Cox proportional hazard and 
Poisson models were used to evaluate the association of SLE with the outcomes, 
adjusting for confounders. The findings suggest SLE is associated with increased risks 
of first severe infection, a greater total number of severe infections and infection-related 
mortality. 
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Chapter 1.  
 
Introduction 
1.1. Background 
Systemic lupus erythematosus (SLE) is a chronic disease with a broad spectrum of 
autoantibodies and clinical manifestations. It is a complex disease in which the body’s 
immune system mistakenly attacks healthy tissues in many parts of the body. Although 
SLE is a relatively rare disease, its burden, in terms of incidence, prevalence and 
economic loss remains underappreciated and poorly understood[1]. Patients with SLE 
are, not surprisingly, likely to endure considerably reduced health-related quality of life. 
Common symptoms include painful and swollen joints, fever, hair loss and red rash[2]. 
The cause of SLE is not clear but presumably caused by a genetic susceptibility coupled 
with environment factor to trigger defects in the immune system. SLE is much more 
common in women than men: women aged 15-45 can be affected about 9 times more 
often than men[3]. Both men and women with SLE have a higher risk of developing 
cardiovascular and cerebrovascular disease and malignancy than individuals without 
SLE, as a consequence of both the disease and its treatments[4, 5]. There have been 
clinical improvements in controlling inflammatory manifestations of SLE, but a recent 
study suggested that survival rates of SLE patients have not improved in recent years[6] 
and are still at least 2-3 fold greater than the general population[7, 8]. 
Infections are a leading cause of morbidity and premature mortality in patients with SLE. 
Previous studies reported that 14-45% of SLE patients had severe infections requiring 
hospitalization and up to 50% of deaths were due to infections[9-12]. In an European 
multicenter lupus cohort of 1000 patients from seven countries, 36% of the patients had 
an infection during follow-up and 25% of all deaths were caused by infection[13], similar 
to reports from British[14] and Spanish cohorts[15]. Furthermore, the largest European 
SLE study on 3658 patients observed that 19% suffered from a severe infection[12]. 
Several factors are associated with infection in SLE: these include advanced age, longer 
disease duration, positive anti-ds DNA antibodies, number of disease manifestations, 
prednisone dose, use of immunosuppressive drugs, disease activity, and decreased 
renal function[16-19]. 
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1.2. Motivation 
Although studies using prevalent and clinic-based lupus cohorts have examined the 
association between SLE and infection, they were subject to an inherent survivorship 
bias as only healthier survivors were included and previous infections and deaths could 
not be included. Other studies used selected samples (e.g., children and women) so 
their conclusions lack generalizability to all SLE patients[20, 21]. The limitations from 
existing studies including selected samples, small sizes and prevalent cohorts can 
negatively affect the accuracy of both the absolute and relative risk estimates of 
infections in SLE at the population level. Consequently, we still do not have a holistic 
picture of the SLE-infection association. 
Population data which encompass all provincially funded healthcare service data shows 
promising opportunities to advance the knowledge and management of the SLE patients 
which cannot be evaluated by the conventional clinical setting with small sample size 
and selective samples. 
To address these knowledge gaps, we conducted a large population-based study of all 
patients with incident SLE between January 1, 1997 and March 31, 2015 in British 
Columbia (BC), Canada.  
1.3. Objective 
The objective of this study is twofold: first, to determine whether SLE is an independent 
risk factor for severe infections and infection-related mortality compared to the general 
population, second, to identify risk factors of severe infections in SLE patients.  
1.4. Outline 
The project is organized as follows: Chapter 2 introduces the study design, statistical 
methods used in survival analysis, the concept of competing risks and the technical 
details of the regression models used to account for competing risks. Chapter 3 
describes the descriptive results of the SLE and non-SLE cohort, increased risks of 
infection and the sensitivity analyses. Chapter 4 provides a brief discussion on findings, 
limitations, and a discussion of future research. 
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Chapter 2.  
 
Methods 
Universal healthcare coverage is available for all residents of the province of British 
Columbia, Canada (4.7 M in 2015)[22]. Population Data BC, stripped of identifying 
information, includes data on all provincially funded healthcare service data from 
January 1, 1990 to March 31, 2015, including all registration information on healthcare 
professional visits[23], hospitalizations[24], cancer registry[25], vital statistics[26] and all 
dispensed medications in outpatient settings for all BC residents since January 1, 
1996[27]. Several population-based studies have been successfully conducted using 
Population Data BC[28-31]. 
Population data are generated for administrative or billing purposes and collected at 
every healthcare encounter. Although not intended for research purposes because of the 
lack of clinical details, Population data have been used worldwide in research for the 
purpose of understanding health trends, monitoring patient outcomes and determining 
the efficacy of various treatments and medical interventions. The main linkable 
databases include the following: 
The Medical Services Plan includes data on all provincially-funded healthcare services, 
such as physician visits, procedures performed, investigations ordered, dates of service, 
types of practitioners (i.e., general practitioners, specialist types), laboratory tests 
ordered, and the diagnosis for which a service was rendered as determined through an 
ICD-9-CM diagnostic code. 
The Hospital Separation File includes information on all hospital admission and 
separation dates, up to 16 diagnostic fields representing the reason for admission 
(primary position) or complications during hospitalization (secondary positions) using 
ICD-9-CM and ICD-10-CM codes, as well as procedures, interventions and surgeries 
performed. 
PharmaNet data includes information on all prescription medications dispensed for all 
residents of BC since 1995, regardless of funding source. This data file includes the date 
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that each prescription was dispensed, its generic drug name, dose, quantity, and days 
supplied. 
The Vital Statistics Files provide information on death, including date of death and 
underlying cause of death (based on ICD-10-CM codes).  
The Registration File provides basic demographic information such as sex, year of birth 
and geographic information. 
The Cancer Registry ascertains and verifies all newly diagnosed cancer cases among 
residents of the province of BC through multiple sources, including pathology and 
haematology laboratories, cancer treatment centres, other provincial registries, and 
death records. 
2.1. Study design and cohort definitions 
Using data from Population Data BC, we assembled a 1:5 matched cohort study with 
incident SLE patients (SLE cohort) compared with age-, gender- and index year-
matched individuals who were randomly selected from the general population (non-SLE 
cohort).  
2.1.1. SLE cohort 
The case definition of incident SLE included the following: 1) age ≥ 18 years; 2) two 
principal International Classification of Disease, Ninth Revision, Clinical Modification 
(ICD-9-CM 710.0) or ICD tenth Revision, Clinical Modification (ICD-10-CM M32.1, 
M32.8, M32.9) codes for SLE at least two months apart within two years from any type 
of physician or hospital visit; and 3) no SLE diagnosis in a seven-year run-in period prior 
to the first ICD code for SLE to ensure incident SLE cases. 99.4% of the SLE patients 
had at least one of the two ICD codes diagnosed by rheumatologists or from the 
hospitalization dataset[32]. This definition has 97.6% sensitivity and 97.5% positive 
predictive value in the Swedish registry data[33]. The date of the second ICD date in the 
pair of ICD codes to confirm SLE was defined as the SLE diagnosis date. Once a patient 
was confirmed to have incident SLE, a look back algorithm was applied to search for 
SLE-related resource use in the patient’s history. The date of the first ever ICD code for 
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SLE was defined as the index date (i.e., SLE onset date), which was the start of the 
study follow-up for a SLE patient.   
2.1.2. Non-SLE Cohort 
2,000,000 randomly selected BC residents registered with the provincial medical 
services plan during the study period were used to establish the comparison non-SLE 
cohort. The randomly selected individuals without any history of SLE were matched to 
SLE patients (1:5) on age, gender, and the assigned SLE index date (i.e., first-ever SLE 
visit) of the matched SLE patient. Because by design the SLE patient was alive between 
the patient’s index date and diagnosis date, to avoid immortal time bias, the 
corresponding selected non-SLE individuals had to remain alive between the assigned 
SLE index date and diagnosis date.  
2.1.3. Ascertainment of Outcomes 
The primary outcome was the first severe infection during follow-up. Severe infections 
were defined as infections necessitating admission to hospital or occurring during a 
hospitalization[34]. Fifty-eight different types of infections (supplementary table S1) were 
selected a priori by a panel of experts and identified using ICD-9 and ICD-10 codes[34]. 
We chose infections necessitating hospitalization as this case definition has a 95.4% 
positive predictive value to identify severe infections[35]. Secondary outcomes were the 
total number of severe infections and infection-related mortality during follow-up. We 
defined the latter secondary outcome as a death with at least one of the above 58 types 
of infections listed as the primary cause of death or as other contributing causes of death 
in the death axis coding as recorded in the individual’s vital statistics record[26].  
2.1.4.  Covariate assessment 
Baseline covariates were assessed within 12 months prior to the index date (first ever 
ICD code for SLE). Covariates included prior hospitalized infections before the index 
date, gender, age, the modified Romano Charlson comorbidity index for administrative 
data [36], baseline medication use categorized as ever use or never use 
(glucocorticoids, fibrates, statins, anti-diabetic medications, anticoagulant therapy, other 
cardiovascular (CVD) drugs, non-steroid anti-inflammatory drugs [NSAIDs], hormone 
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replacement therapy [HRT], cyclooxygenase-2 [Cox-2]  inhibitors, and oral 
contraceptives), comorbidities (hypertension, cerebrovascular disease, alcoholism, 
ischemic heart disease, myocardial infarction, congestive heart failure, depression, 
malignancy and chronic obstructive pulmonary disease [COPD] related diseases), and 
health resource utilization (number of outpatient visits and hospitalizations).  
2.2. Statistical analyses 
Survival analysis methods are often used to analyze the time until an event has 
occurred. One way that survival data differs from other types of data is through 
censoring. The most common type of censoring is right censoring where study ends 
before the subject experiences the event or drops out of the study prematurely before 
the event occurs. In this case, the event time is not known but the event is assumed to 
take place following the censoring time.  
One concept to understand survival data is the survival function that gives the probability 
that a patient will survive beyond any specified time t. That is,  
S(t) = P(T > t) = 1 − F(t) 
where F(t) is the cumulative distribution function of the lifetime, T. Estimation of the 
survival function may be carried out parametrically semi-parametrically or non-
parametrically, depending on the model assumption.  
A simple and widely used non-parametric estimator of the survival function is the 
Kaplan-Meier estimator where the number of events that have occurred for each time 
interval. The survival curves using Kaplan-Meier estimates, are of a stepwise form such 
that the survival probability only changes at times when an event is observed, or 
censoring occurs. One limitation with the Kaplan-Meier estimator is that we cannot 
adjust for predictors or make predictions about a right censored event time without 
making additional assumptions. 
Another key concept is the hazard function which is defined as  
h(t) = lim
∆t→0
(
Prob (t ≤ T < t + ∆t)| T ≥ t
∆t
)  
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 The hazard function, which is a function of time, describes the instantaneous rate of 
occurrence of the event of interest in subjects who are still at risk of the event. Cox 
Proportional Hazards Model is often used to relate the hazard function to covariates, 
including age, gender, social economic status, and other characteristics. The Cox 
Proportional Hazards Model is usually written in terms of the hazard function as follows 
h(t)=h0(t)exp(Xβ) 
where h0(t), baseline hazard function or the hazard for a reference individual with 
covariate values 0 and X denotes a set of explanatory variables, and β denotes the 
associated regression parameters. The coefficients are log-hazard ratios. It is semi-
parametric because it makes a parametric assumption concerning the effect of the 
predictors(β) on the hazard function but makes no assumption regarding the nature of 
the hazard function itself. This method uses the partial likelihood to estimate the 
parameters, and parameter estimates in the method are obtained by maximizing partial 
likelihood function. The partial likelihood is motivated by conditioning on the observed 
failure time ti and given by: 
𝐿(𝛽) = ∏
exp (𝛽′𝑥𝑖)
∑ exp (𝛽′𝑥𝑙)𝑙∈𝑅(𝑡𝑖)
𝑘
𝑖=1
 
In parametric estimation, because event time is non-negative and rarely normally 
distributed, distributions such as gamma, Weibull and exponential with non-negative and 
extreme values are more commonly used. These distributions proved to be good fit for 
censored or uncensored data.  
With the hazard function, the survival function is specified as 
S(t) = exp[−H(t)] 
Where  
H(t) = ∫ ℎ(𝑢)du
𝑡
0
 
 
We calculated the incidence rates (IRs) of outcomes per 1,000 person-years. For the 
primary outcome (first severe infection during follow-up), individuals were followed from 
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the index date until they either experienced the first severe infection, died, left BC or the 
study period ended, whichever happened first. To compute IRs for the secondary 
outcomes (total number of severe infections and infection-related death), follow-up 
ended at death, migration out of BC or the end of study, whichever occurred first, but 
continued beyond first severe infection. 
To further adjust for potential confounders, multivariable Cox proportional hazard (PH) 
models [37] were used to compute the adjusted hazard ratios (aHR) of infections and 
infection-related mortality for the SLE cohort compared to the non-SLE cohort, adjusting 
for baseline variables. The variables adjusted in the model were demographic, health 
care resource utilization, medication use, comorbidities and prior hospitalized infection. 
The effects of risk factors on infections were estimated in the SLE cohort and were 
expressed in hazard ratios with 95% confidence intervals. Additionally, we used Poisson 
regression with over-dispersion [38] to determine the adjusted rate ratios (aRR) of total 
number of severe infections that occurred during follow-up for SLE compared with the 
non-SLE cohort controls and to identify risk factors of recurrent severe infections for the 
SLE patients.  
2.3. Sensitivity analyses 
The survival analyses we conducted above rely on the important assumption of 
independent or noinformative censoring [39] which suggests that at a given time, the 
subjects being followed have the same risk for the occurrence of the event as those who 
remained under follow-up. However, this assumption may not hold true in the presence 
of competing risk. A competing risk is an event which precludes the occurrence of the 
event of interest. For instance, when the primary outcome was time to infection, death 
serves as a competing risk. A subject who died is no longer at risk of infection. 
Competing risks are common in studies where different events can occur and one is 
interested in which event occurred first. 
When analyzing survival data in the presence of competing risks, censoring subjects 
when a competing event occurs is problematic because it is not realistic to assume the 
subjects who had competing events can be represented by those who remain alive thus 
violating the assumption of noninformative censoring. In many practical applications, 
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censoring subjects when competing event occurs generally lead to overestimation of the 
cumulative incidence of an event in the presence of the competing events [40].  
The Cumulative Incidence Function (CIF), defined as 1 – S(t), allows for estimation of 
the incidence of the occurrence of an event while taking competing risk into account. 
Estimating the incidence of an event as a function of follow-up time provides important 
information on the absolute risk of an event. The cumulative incidence function for the 
kth cause is defined as: CIFk (t) = P(T ≤ t,D = k ), where D is a variable denoting the type 
of event that occurred. The difference resides in the fact that in the presence of 
competing risks, only 1 event can occur which precludes the occurrences of other 
events. CIFk (t) is therefore the probability of kth event at or before time t and before 
other events occur.  
When analyzing data with competing events, two different types of hazard functions are 
of interest: the cause-specific hazard function and the subdistribution hazard function. 
The cause-specific hazard function is defined as 
hk
cs(t) = lim
∆t→0
(
Prob (t ≤ T < t + ∆t, K = k)| T ≥ t
∆t
)  
The cause-specific hazard function denotes the instantaneous rate of occurrence of the 
kth event in subjects who have never experienced any of the different types of events. 
On the other hand, the subdistribution hazard function is defined as  
hk
sd(t) = lim
∆t→0
(
Prob (t ≤ T < t + ∆t, K = k|T > t ∪ (T < t ∩  K ≠ k) 
∆t
)  
The subdistribution hazard function denotes the risk of failure from the kth event in 
subjects who have not yet experienced an event of type k. Note that the risk set for the 
subdistribution hazard function differs from that for the cause specific hazard function, 
which only includes those who are currently event free. 
There are 2 different hazard regression models accounting for the competing risks: 
modeling the cause-specific hazard and modeling the subdistribution hazard function. 
The subdistribution hazard model has also been described as a CIF regression model 
because one may directly predict the cumulative incidence for an event of interest using 
the usual relationship between the hazard and the incidence function under the 
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proportional hazards model. Thus, the subdistribution hazard model allows one to 
directly estimate the effect of covariates on the cumulative incidence function for the 
event of interest. 
As a result of modelling different hazard function, each model has its unique 
interpretation. The subdistribution hazard model is preferable when the focus is on 
estimating incidence or predicting prognosis in the presence of competing risks whereas 
cause-specific hazard models may be more appropriate for addressing epidemiological 
questions of etiology. The rationale is a regression coefficient from a cause-specific 
hazard model can be interpreted as the relative effect of the corresponding covariate on 
the relative increase in the rate of the occurrence of the primary event in subjects who 
are currently event free. In comparison, prediction models are often interested in 
estimating the absolute incidence where one may link the effect of covariates to the 
cumulative incidence for an event of interest in the subdistribution regression model. 
 
To examine the robustness of our results, we performed three sensitivity analyses. First, 
to assess the effect of an unmeasured confounder (i.e. smoking), we calculated the aHR 
and aRR by adding the simulated unmeasured confounder in the multivariable Cox and 
Poisson models, respectively. To simulate the smoking distribution for individuals, we 
used a smoking prevalence ranging from 42% to 46% in the SLE cohort[41], a 
prevalence of 31% for the non-SLE cohort  (corresponding to the estimated prevalence 
of smoking for the general population of Canada aged 15 and older)[42] and odds ratios 
(OR) for the association between smoking and infection ranging from 2.20-2.60[43]. 
Second, we used the Fine-Gray method[44] to compute the crude CIF of first severe 
infections and infection-related mortality, while accounting for competing risks of death 
due to causes unrelated to infection. Gray’s Test [45] was used for comparing  the crude 
CIFs between the two cohorts. To further adjust for potential confounders, multivariable 
subdistribution proportional hazard models were used[46]. Last, because the medication 
data were fully captured for all BC residents only after January 1,1996 [27], there existed 
uncertainty about the baseline medication data (12 months prior to the index date) for 
611 SLE cases whose index date was before January 1, 1997. We therefore conducted 
sensitivity analyses that excluded these 611 SLE cases. 
All statistical analyses used SAS V.9.4 (SAS Institute, Cary, North Carolina, USA).  
11 
2.4. Ethical approval 
No personal identifying information was made available as part of this study. Procedures 
used were in compliance with British Columbia’s Freedom of Information and Privacy 
Protection Act. Ethical approval was obtained from the University of British Columbia’s 
Behavioral Research Ethics Board (H15-00887). 
2.5. Data availability 
All the data are made available via Population Data BC (https://www.popdata.bc.ca/). 
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Chapter 3.  
 
Results 
3.1. Baseline Characteristics  
Table 1 summarizes the baseline characteristics for SLE and non-SLE cohorts. During 
the study period, we identified 5,169 newly diagnosed SLE patients (86% female) with 
mean age of 46.9 years at the index date (first ever ICD code for SLE). The mean and 
median time between the index date (first ever ICD SLE code) and the SLE diagnosis 
date (the second ICD code in the pair of ICD codes to confirm SLE) was 3.1 and 0.9 
years, respectively.  
Compared to the non-SLE cohort, the SLE cohort had significantly higher numbers of all 
outpatient visits and hospitalizations, greater Charlson comorbidity index scores and a 
higher prevalence of all selected comorbidities and prior hospitalized infection. In the 
SLE cohort, the most used prescriptions during 12 months prior to the index date were 
NSAIDs and Cox-2 inhibitors (39%), glucocorticoids (25%), followed by CVD drugs 
excluding anticoagulant therapy (20%). 
3.2. Time to the first severe infection  
During follow-up we observed 955 first severe infections (mean follow-up time of 9.4 
years) in the SLE cohort compared with 1,988 (mean follow-up time of 10.1 years) in the 
non-SLE cohort. The IR for severe infections in the SLE cohort was 19.7 events per 
1,000 person-years, while the IR in the non-SLE cohort was 7.6 events per 1,000 
person-years. Among the patients who had infections, the mean time to first infection 
was 7.4 and 7.9 years from the index date for the SLE and non-SLE cohorts, 
respectively.   
Multivariable Cox PH models were used to estimate the association of SLE with the first 
post-SLE-onset infection. The age- and gender-adjusted HR for first severe infection for 
SLE was 2.67 (95% CI, 2.47-2.88) compared to the non-SLE cohort. The fully aHR 
adjusting for all baseline covariates was 1.82 (95% CI, 1.66-1.99, Table 2). 
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The risk factor analysis using the SLE cohort (Table 3) revealed that the use of 
glucocorticoids (aHR= 1.34, 95% CI; 1.16-1.55) and CVD medications excluding 
anticoagulant therapy (aHR=1.43, 95% CI; 1.23-1.68) were statistically significant risk 
factors for new severe infections. Other independent risk factors identified by the 
multivariable analysis showed having a hospitalized infection, congestive heart failure, 
malignancy or a higher number of visits to physicians and hospitals within 12 months 
prior to the index date, greater Charlson comorbidity index and older age at the index 
date, male sex were also positively associated with first severe infections. Higher 
income, on the other hand, was negatively associated the first severe infections. 
3.3. Total number of severe infections  
The SLE cohort had a total of 1,898 severe infections, and 363 SLE patients (7%) had 
recurring severe infections with a range of 2-20 episodes, while the non-SLE cohort had 
3,114 severe infections of which 579 individuals (2%) had recurring severe infections 
with a range of 2-15 episodes. In the multivariable over-dispersed Poisson regression 
analysis for rate of severe infection, SLE was also associated with an increased risk of a 
greater total number of severe infections after adjusting for baseline covariates (age- 
and gender- adjusted RR=3.28 (95% CI, 2.90-3.72)). The fully aRR was 2.07 (95% CI, 
1.82-2.36, Table 2).  
In risk factor analysis (Table 3) for recurrences of severe infections in SLE patients, 
NSAIDs and Cox-2 inhibitors, glucocorticoids, anticoagulant therapy and CVD drugs 
excluding anticoagulant therapy were risk factors for recurring severe infections. Other 
risk factors (older age, male sex, prior hospitalized infection, hypertension, congestive 
heart failure, COPD-related diseases, depression, malignancy and greater Charlson 
comorbidity index) were also associated with a higher frequency of severe infections 
while higher income was associated with a lower rate of severe infections.  
3.4. Mortality related to infection  
During follow-up, there were 539 deaths in SLE patients of which 114 (21%) were 
related to severe infection (Table 2). In comparison, in the non-SLE cohort, we observed 
1,495 deaths in total and 269 (18%) deaths were related to severe infection (Table 2). 
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The incidence rate ratio for infection-related mortality between SLE and non-SLE cohort 
was 2.17 (95% CI, 1.76-2.73, Table 2). The age- and gender- adjusted HR was 2.34 
(95% CI, 1.88-2.91, Table 2). After further adjustment for baseline covariates, the aHR of 
infection-related mortality for SLE compared to non-SLE cohort was 1.61 (95% CI, 1.24-
2.08, Table 2).  
Older age, male sex and the number of hospitalizations were associated with higher risk 
of deaths caused by infection in SLE patients while glucocorticoids and 
immunosuppressive drugs were not found to be significant risk factors (Table 3). Higher 
income was a protective factor (HR ranging from 0.04-0.49 for different levels of income) 
for infection-caused mortality. 
3.5. Sensitivity analyses 
We performed three sensitivity analyses. First, multivariable Cox PH models were used 
to estimate the association of SLE with the first post-SLE-onset infection and infection-
related mortality adjusting for baseline covariates and the unmeasured confounder, 
smoking history. Similarly adjusting for baseline covariates and smoking history, a 
Poisson count model was used to estimate the association of SLE with the total number 
of severe infections. Table 4 reports the comparison of the results from the primary 
analysis with sensitivity analyses. The aHR of first severe infection and infection-related 
mortality for SLE and aRR of total number of infections for SLE remained significant, but 
attenuated at values of 46% smoking prevalence in the SLE cohort and OR of 2.60 for 
the association between smoking and infection (Table 4). Secondly, after accounting for 
the competing risk of death due to causes unrelated to infection, CIFs (Figure 1 and 2) 
and Gray’s tests show patients in the SLE cohort had a statistically significant faster rate 
to their first severe infection and infection-related death than individuals in the non-SLE 
cohort (P-value < 0.001). Using subdistribution models, the aHR also remained 
significant, but the effect sizes were slightly attenuated for infection-related mortality 
(Table 4). Last, the aHR and aRR remained statistically significant for severe infection 
and infection-related mortality when using individuals with index date after January 1, 
1997 only (Table 4).  
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Chapter 4.  
 
Discussion 
4.1. Summary 
To our knowledge, this is the first study to evaluate the risk of severe infections in a large 
population-based and incident SLE cohort. We observed that almost one in five SLE 
patients developed severe infection. Compared to the general population, SLE patients 
demonstrated significantly increased risks for first severe infection (1.8-fold), total 
number of severe infections (2.1-fold) and infection-related mortality (1.6-fold). These 
risks were independent of traditional risk factors for infection and the results remain 
robust in the presence of an unmeasured confounder (smoking) and competing risk of 
death. The assumption of proportional Hazards was met by the global Schoenfeld 
residuals test for the model. Compared to the studies with selected samples, our findings 
are generalizable to all BC residents.   
 The observed cumulative incidence of infection in 19% of all 5,169 SLE patients is 
consistent with previous studies using prevalent cohorts [9-12]. We also observed that 
21% of overall mortality was related to severe infection, a percentage which is very close 
to a US study conducted in 1995 using a prevalent cohort over a study period of 11 
years[47]. In terms of risk difference, compared to the general population, there was an 
increased risk for infections among patients with SLE. These findings are in agreement 
with previous studies of severe infections in SLE patients[14, 15]. We deem that our 
findings are generalizable to the general SLE population due to the large population-
based incident SLE cohort, as compared with previous studies that had a small sample 
size from selected samples (< 150 hospitalized patients, for example[7,8]) Our study 
also has the advantage of being able to adjust for important infection risk factors such as 
comorbidities, income level, medications, prior hospitalized infection, unmeasured 
confounders and competing risks.  
The observed increased risk of infection in SLE patients may be a result of both intrinsic 
and extrinsic factors. Intrinsic factors include the immune system dysfunctions, with 
more active SLE with impaired chemotaxis and phagocytosis of macrophages and 
polymorphonuclear cells diminishing the body’s immune complexes and abnormal T cell 
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production[48]. On the extrinsic side, the use of immunosuppressive medications and 
glucocorticoids has been studied in previous studies[49-51]. These medications inhibit 
the immunologic network and therefore decrease the resistance to a wide variety of 
bacterial, viral, protozoal, and fungal agents[50]. Conversely the elevated risk for 
infection due to the immunosuppressive actions may be counterbalanced by the benefit 
of these medications in controlling inflammation[34]. This work examines the total effect 
of these intrinsic and extrinsic factors on infections. As such, we did not adjust for the 
medication uses (e.g., glucocorticoids use) during follow up because this would mean 
adjusting for mediators which is inappropriate for studying the total risk of having SLE on 
infections. Future research can focus on quantifying the relative contributions of these 
intrinsic and extrinsic factors on the increased infection risk in SLE patients. We note 
that in such analysis, simply entering the use of medications during follow-up as time-
varying covariates in a traditional time-dependent multivariable Cox model can yield 
biased effect estimates because medication use is both a time-dependent confounder 
and a mediator. 
4.2. Limitations 
Our study has limitations common to observational studies that use administrative data. 
First, uncertainty around the diagnostic accuracy of SLE cannot be completely ruled out. 
However, we used a strict algorithm with high positive predictive value (97.5%) for SLE 
diagnostic accuracy. Nevertheless, misclassification would be a conservative bias where 
the observed effect would bias the estimates towards the null. Second, due to 
inaccuracy in prescription data (including glucocorticoid use at baseline) before 1996, we 
conducted a sensitivity analyses on individuals with index date on or later than January 
1, 1997 only. The corresponding results remained robust. Although we adjusted for all 
known risk factors for infections available in our data, there are other risk factors such as 
smoking for which data is currently unavailable. Administrative data typically do not 
contain physician assessments or related assessments (e.g., disease activity, weight 
and race). The lack of clinical information causes confounding by unobservables. 
Nonetheless, in our sensitivity analyses adjusting for plausible unmeasured 
confounders, the results remained statistically significant for each of the outcomes using 
values of 46% prevalence of smoking in the SLE cohort and an odds ratio of 2.60 for the 
association between smoking and the infection. Events such as leaving BC were 
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censored because such information is also not available. Information about the health 
service renewal status for individuals is helpful to determine whether and when 
individuals leave the province. Last, since there is a lack of details for non-hospitalized 
infection in administrative data, there may have been severe infections (e.g., endemic 
mycoses) that didn’t result in hospitalization[52]. As a result, our results may have 
underestimated the risk of infections. 
 
Despite the limitations, our study has some strengths. First, we used a large Canadian 
administrative dataset with a substantial timespan from 1997-2015 based on the entire 
SLE population in BC, which makes our results more generalizable. To the best of our 
knowledge, this is the largest SLE cohort assembled to date to study the relationship 
between SLE and infection. Second, using an incident cohort can avoid the survival bias 
associated with prevalent cohorts[53]. Finally, unlike previous studies, we performed 
sensitivity analyses to account for the effect of unmeasured confounders, competing risk 
of death and inaccuracy of the prescription data before 1996 which make our results 
robust and less biased.  
Our findings highlight the risk for severe infection and shed light on important 
implications for SLE patients and their treating physicians. Increased awareness of the 
risk of infections can identify their early signs and potentially prevent hospitalizations. 
We suggest that in the clinical setting, physician visits provide an opportunity to promote 
infection prevention behavior for SLE patients. For instance, in some cases, infections 
may be prevented with vaccinations[54], and regular physician consultations could be 
valuable for awareness and promotion of appropriate vaccination strategies.  
4.3. Future work 
There is a need for additional research on the risk of infection in SLE patients given the 
large burden and possibility for prevention. Future studies should aim to 
comprehensively examine risk factors for severe infection in SLE patients in order to 
develop and implement strategies for the prevention of severe infection and infection-
related mortality. One plausible reason for the increased risk of infection in SLE patients 
is the inflammation  that may lead to the use of glucocorticoids for disease 
management[34]. Appropriate and opportune management of disease activity in SLE 
can decrease inflammation and potentially mitigate the risk of severe infections while 
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minimizing the use of glucocorticoids. In order to reduce the infection-related morbidity 
and mortality in SLE, evidence on the risk factors for and burden of inflammation in SLE 
is required.  
When the straightforward rule-based treatment guidelines are difficult to be established, 
how to optimize the sequence of specific treatments for the patients with SLE becomes a 
central problem for the treating doctors to make clinical recommendations. The statistical 
learning methods provides a promising data-driven technique to explore and examine 
the best strategies[55]. Further studies are warranted to leverage on the administrative 
data and modern statistical methods to learn about the effect of drug combinations in the 
long run.  
In summary, this is the first comprehensive population-based study assessing the SLE-
infection association. Our study demonstrates that one in five SLE patients developed 
severe infections and 21% of overall mortality was related to severe infection. SLE 
patients have 82%, 107% and 61% increased risks of developing the first severe 
infection, a greater total number of severe infections and infection-related mortality 
compared to the general population, demonstrating that SLE is an independent risk 
factor for severe infection and infection-related mortality. This result expands on the 
findings of previous studies and has important implications for the prevention, screening 
and treatment of infections. We recommend a closer surveillance for severe infections in 
SLE patients and risk assessment for severe infections for SLE patients after diagnosis. 
Further studies are warranted to further identify risk factors for infections in SLE patients 
to develop personalized treatment regimens and to select treatment in practice by 
synthesizing patient information.  
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Tables 
Table 1  Baseline characteristics of individuals with SLE and without SLE   
Variable * SLE cohort 
N=5,169 
Non-SLE cohort 
N=25,845 
Demographics 
Age, mean (median) 46.9 (47) 46.9 (47) 
Female, n (%) 4,384 (86.2%) 22,270 (86.2%) 
Rural, n (%) 785 (15.2%) 3,334 (12.9%) 
Neighborhood income quintile, n (%)   
1 (Lowest) 1,014 (19.6%) 4,380 (17.0%) 
2 950 (18.4%) 4,558 (17.6%) 
3 978 (18.9%) 4,577 (17.7%) 
4 922 (17.8%) 4,841 (18.7%) 
5 (Highest) 858 (16.6%) 4,762 (18.4%) 
Unknown 
 
447 (8.7%) 2,727 (10.6%) 
Health Resource Utilization *,  
  mean (median) 
Number of outpatient visits  22.9 (19.0) 7.0 (10.6) 
Number of hospitalizations  0.1 (0.0) 0.0 (0.0) 
 
Comorbidities *, n (%) 
Alcoholism 48 (0.9%) 133 (0.5%) 
Hypertension 781 (15.1%) 3,253 (12.6%) 
Cerebrovascular accidents 64 (1.2%) 90 (0.4%) 
Ischemic heart disease 345 (6.7%) 697 (2.7%) 
Myocardial infarction 31 (0.6%) 77 (0.3%) 
Congestive heart failure 82 (1.6%) 161 (0.6%) 
COPD-related diseases 131 (2.5%) 329 (1.3%) 
Depression 722 (14.0%) 2,284 (8.8%) 
Malignancy 261 (5.1%) 856 (3.3%) 
Charlson comorbidity index, mean (median) 
 
0.6 (0.0) 0.2 (0.0) 
Medications *, n (%)    
NSAIDs  2,030 (39.3%) 3,697 (14.3%) 
HRT 492 (9.5%) 1,434 (5.6%) 
Glucocorticoids 1,281 (24.8%) 737 (2.9%) 
Anticoagulant therapy 166 (3.2%) 220 (0.9%) 
CVD drugs excluding anticoagulant therapy 1,049 (20.3%) 3,446 (13.3%) 
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Variable * SLE cohort 
N=5,169 
Non-SLE cohort 
N=25,845 
Fibrates/statins 297 (5.5%) 1,372 (5.3%) 
Anti-diabetic medications 169 (3.3%) 
 
854 (3.3%) 
History of Infection *  
Prior hospitalized infection 
 
1,105 (21.4%) 
 
3,095 (12.0%) 
Abbreviations: SLE, systemic lupus erythematosus; SD, standard deviation; COPD, chronic obstructive pulmonary 
disease; NSAIDs, non-steroidal anti-inflammatory drugs including cyclooxygenase-2 inhibitors; HRT, hormone 
replacement therapy; CVD, cardiovascular diseases. 
*All baseline characteristics were measured over one year prior to the start of follow-up except that age was measured 
at the start date of the follow-up.  
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Table 2  Risk of severe infection in SLE relative to non-SLE during follow-up 
Post-SLE diagnosis first severe infection 
 SLE cohort 
N=5,169 
Non-SLE cohort 
N=25,845 
No. of events 955 1,988 
IR per 1,000 person-years 19.74 7.61 
IRR (95% CI) 
Age and gender adjusted HR 
(95% CI) 
2.59 (2.39-2.80) 
2.67 (2.47-2.88) 
 
1.00 
1.00 
Fully adjusted HR* (95% CI) 1.82 (1.66-1.99) 1.00 
Post-SLE total number of severe infections 
Infection episodes 1,898 3,114 
IR per 1,000 person-years 38.4 11.87 
IRR (95% CI) 
Age and gender adjusted rate 
ratio (95% CI) 
3.24 (3.06-3.43) 
3.28 (2.90-3.72) 
 
1.00 
1.00 
Fully adjusted rate ratio* (95% 
CI) 
2.07 (1.82-2.36) 1.00 
Infection-related mortality 
No. of infection-related death 
events 
114 269 
IR per 1,000 person-years 2.17 1.00 
IRR (95% CI) 
Age and gender adjusted HR 
(95% CI) 
2.20 (1.76-2.73) 
2.34 (1.88-2.91) 
1.00 
1.00 
Fully adjusted HR* (95% CI) 1.61 (1.24-2.08) 1.00 
Abbreviations: SLE, systemic lupus erythematosus; IR, incidence rate; IRR, incidence rate ratio; HR, hazard ratio; CI, 
confidence interval. 
*Adjusted for covariates listed in Table 1. 
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Table 3  Risk factors for severe infection outcomes in SLE* 
  Post-SLE first severe 
infection Recurring severe infections 
Infection-caused 
death 
 
Risk factors  
HR (95% CI) 
P-value 
RR (95% CI) 
P-value 
HR (95% CI) 
P-value 
Demographics     
Age (reference:47-) 1.51 (1.32-1.74) 
<.0001 
1.36 (1.23-1.50) 
<.0001 
5.47 (1.81- 16.7) 
0.0025 
Sex (reference: 
female) 
1.24 (1.04-1.47) 
0.0173 
1.25 (1.11-1.42) 
0.0004 
2.68 (1.08-6.64) 
0.0338 
Neighborhood 
Income Quintile 
   
(reference: 1 being 
Lowest) 
    
 
2 
 
0.92 (0.75-1.12) 
0.4130 
0.85 (0.73-0.98) 
0.0216 
0.28 (0.08-1.11) 
0.0712 
3 
 
0.78 (0.63-0.96) 
0.0187 
0.80 (0.69-0.93) 
0.0028 
0.49 (0.67-0.90) 
0.2103 
4 
 
0.77 (0.62-0.95) 
0.0149 
0.68 (0.58-0.80) 
<.0001 
0.11 (0.01-0.84) 
0.0336 
5 (Highest) 
 
0.67 (0.54-0.84) 
0.0004 
0.69 (0.59-0.81) 
<.0001 
0.04 (0.12-0.91) 
0.0404 
Unknown 
 
0.56 (0.44-0.72) 
<.0001 
0.93 (0.81-1.09) 
0.4912 
0.28 (0.06-1.24) 
0.0936 
Health Resource 
Utilization 
    
Number of outpatient 
visits (Reference: 
23-) 
1.29 (1.12-1.48) 
0.004 
1.28 (1.16-1.42) 
<.0001 
 
 
Number of 
hospitalization 
(Reference: 1-) 
2.98 (2.26-3.95) 
<.0001 
2.78 (2.33-3.31) 
<.0001 
11.08 (3.61-34.00) 
<.0001 
Number of 
rheumatologist visits 
(Reference: 1-) 
  0.78 (0.67-0.91) 
0.0013 
 
 
 
Comorbidities     
Ischemic heart 
disease 
 0.79 (0.66-0.93)  
0.0046  
 
Congestive heart 
failure 
1.53 (1.07-2.20)  
0.0194  
1.95 (1.58-2.40)  
<.0001  
 
23 
  Post-SLE first severe 
infection Recurring severe infections 
Infection-caused 
death 
 
Risk factors  
HR (95% CI) 
P-value 
RR (95% CI) 
P-value 
HR (95% CI) 
P-value 
Depression 
 
 1.21 (1.07-1.37)  
0.0019  
 
Malignancy 
 
1.41 (1.09-1.82)  
0.0084  
1.25 (1.05-1.49)  
0.0137  
 
Charlson comorbidity 
index (Reference: 
0.6-) 
1.29 (1.12-1.49)  
0.0006  
 
1.43 (1.29-1.59)  
<.0001  
 
 
Medications     
NSAIDs &      Cox-2 
inhibitors 
1.34 (1.16-1.55) 
<.0001 
1.16 (1.05-1.27) 
0.0025 
 
 
Glucocorticoids 
 
1.43 (1.23-1.68) 
<.0001 
1.37 (1.24-1.52) 
<.0001 
 
Anticoagulant 
therapy 
 1.33 (1.10-1.61) 
0.0034 
 
CVD drugs excluding 
anticoagulant 
therapy 
 1.33 (1.18-1.49) 
<.0001 
 
Infection History     
Prior hospitalized 
infection (reference: 
No) 
1.71 (1.49-1.97) 
<.0001 
1.95 (1.77-2.15) 
<.0001 
 
 
* All variables listed in Table 1 were selected for Cox and Poisson models using stepwise selection (P<0.15 for entry, 
P>0.05 for exit). Only variables selected in at least one of the above three models are reported in this table. 95% CI, 
95% confidence interval; HR, hazard ratio; RR, rate ratio; COPD, chronic obstructive pulmonary disease; NSAIDs, non-
steroidal anti-inflammatory drugs; Cox-2, cyclooxygenase-2; HRT, hormone replacement therapy. 
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Table 4  Sensitivity analyses for the risk of severe infection and infection-
related mortality in SLE 
Analyses 
 Post-SLE first  
severe infection 
Post-SLE Total number 
of severe infections 
Infection-
related 
 death 
aHR (95% CI)* aRR (95% CI)* aHR (95% CI)* 
Primary analyses 1.82 (1.66-1.99) 2.07 (1.82-2.36) 1.61 (1.24-2.08) 
Sensitivity analyses modeling smoking 
with 
prevalence = 42% and OR = 2.2 
1.68 (1.54-1.84) 1.93 (1.81, 2.07) 1.56 (1.20-2.01) 
Sensitivity analyses modeling smoking 
with  
prevalence = 42% and OR = 2.6 
1.64 (1.50-1.80) 1.89 (1.77-2.02) 1.53 (1.19-1.99) 
Sensitivity analyses modeling smoking 
with 
prevalence = 46% and OR = 2.2 
1.65 (1.51-1.81) 1.90 (1.78-2.04) 1.54 (1.19-2.00) 
Sensitivity analyses modeling smoking 
with 
prevalence = 46% and OR = 2.6 
1.60 (1.47-1.76) 1.85 (1.73-1.98) 1.52 (1.18-1.97) 
Sensitivity analyses accounting for        
competing risk of death due to causes        
unrelated to infection 
1.85 (1.68-2.03) NA 1.51 (1.16-1.96) 
Sensitivity analyses excluding cases 
with  
index date earlier than 1997, January 1 
1.76 (1.59-1.94) 1.95 (1.81-2.10) 1.57 (1.19-2.08) 
*Adjusted for covariates listed in Table 1. 
NA= not applicable 
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Figures 
Figure 1  Cumulative incidence functions of first severe infection among SLE 
and non-SLE. Cumulative incidence was estimated adjusting for 
other-causes of death as competing events. 
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Figure 2  Cumulative incidence functions of infection-related death among 
SLE and non-SLE. Cumulative incidence was estimated adjusting for 
other-causes of death as competing events. 
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Appendix 
Table S1: ICD-9 and ICD-10 codes for infection 
ICD-9 ICD-10 
038 041 053 054 460 461 462 463 464 
465 466 
A40 A41 J00 J01 J02 J03 J04 J05 J06 
480 481 482 483 484 485 486 487 488 
590 
J09 J10 J11 J12 J13 J14 J15 J16 J17 J18 
597 599 601.0 601.1 601.2 601.3 601.4 
604 616.1 
J20 J21 J22 L00 L01 L02 L03 L04 L05 
L06 
616.2 616.3 616.4 647 670 680 681 682 
684 685 
L07 L08 N30 N34 N37 N39 N41.0 N41.3 
N45 
686 658.4 670.0 615.0 615.9 646.6 659.2 
659.3  
N71.0 N71.9 N76.0 N76.2 N77 O411 O85 
O86 
672 760.2 771 999.3 659.3 672 76.02 
771 999.3 
O23 O75.2 O75.3 P35 P36 P37 P38 P39 
 
ICD-9 
038 Septicemia 
041 Bacterial infection in conditions classified elsewhere and of unspecified site 
053 Herpes zoster 
054 Herpes simplex 
460 Acute nasopharyngitis 
461 Acute sinusitis 
462 Acute pharyngitis 
463 Acute tonsillitis 
464 Acute laryngitis and tracheitis 
465 Acute upper respiratory infections of multiple or unspecified sites 
466 Acute bronchitis and bronchiolitis 
480 Viral pneumonia 
481 Pneumococcal pneumonia 
482 Other bacterial pneumonia 
33 
483 Pneumonia due to other specified organism 
484 Pneumonia in infectious diseases classified elsewhere 
485 Bronchopneumonia, organism unspecified 
486 Pneumonia, organism unspecified 
487 Influenza 
488 Influenza due to identified avian influenza virus 
590 Infections of kidney 
597 Urethritis, not sexually transmitted, and urethral syndrome 
599 Other disorders of urethra and urinary tract 
601.0 Acute prostatitis 
601.1 Chronic prostatitis 
601.2 Abscess of prostate 
601.3 Prostatocystitis 
601.4 Prostatitis in diseases classified elsewhere 
604 Orchitis and epididymitis 
616.1 Vaginitis and vulvovaginitis 
616.2 Cyst of Bartholin's gland 
616.3 Abscess of Bartholin's gland 
616.4 Other abscess of vulva 
647 Infectious and parasitic conditions in the mother classifiable elsewhere, but 
complicating pregnancy, childbirth, or the puerperium 
670 Major puerperal infection 
680 Carbuncle and furuncle 
681 Cellulitis and abscess of finger and toe 
682 Other cellulitis and abscess 
683 Acute lymphadenitis 
684 Impetigo 
34 
685 Pilonidal cyst 
686 Other local infections of skin and subcutaneous tissue 
658.4 Infection of amniotic cavity 
670 Major puerperal infection 
615 Inflammatory diseases of uterus, except cervix 
615.9 Unspecified inflammatory disease of uterus 
646.6 Infections of genitourinary tract in pregnancy 
659.2 Maternal pyrexia during labor, unspecified 
659.3 Generalized infection during labor 
672 Pyrexia of unknown origin during the puerperium 
760.2 Maternal infections 
771 Infections specific to the perinatal period 
999.3 Other infection 
 
ICD-10 
A40 Streptococcal sepsis 
A41 Other sepsis 
J00 Acute nasopharyngitis [common cold] 
J01 Acute sinusitis   
J02 Acute pharyngitis   
J03 Acute tonsillitis   
J04 Acute laryngitis and tracheitis   
J05 Acute obstructive laryngitis [croup] and epiglottitis   
J06 Acute upper respiratory infections of multiple and unspecified sites   
J09-J18 Influenza and pneumonia   
J20-J22 Other acute lower respiratory infections   
35 
L00-L08 Infections of the skin and subcutaneous tissue   
N30 Cystitis   
N34 Urethritis and urethral syndrome 
N37 Urethral disorders in diseases classified elsewhere 
N39 Other disorders of urinary system   
N41.0 Acute prostatitis   
N41.3 Prostatocystitis   
N45 Orchitis and epididymitis   
N71.0 Acute inflammatory disease of uterus   
N71.9 Inflammatory disease of uterus, unspecified 
N76.0 Acute vaginitis   
N76.2 Acute vulvitis   
N77 Vulvovaginal ulceration and inflammation in diseases classified elsewhere   
O41.1 Infection of amniotic sac and membranes   
O85 Puerperal sepsis   
O86 Other puerperal infections   
O23 Infections of genitourinary tract in pregnancy   
O75.2 Pyrexia during labour, not elsewhere classified   
O75.3 Other infection during labour   
P35 Congenital viral diseases   
P36 Bacterial sepsis of newborn   
P37 Other congenital infectious and parasitic diseases 
P38 Omphalitis of newborn with or without mild haemorrhage   
P39 Other infections specific to the perinatal period 
 
